They did better than expected in both revenue and profit.
I am so ashamed of buying this dog I am now changing my identity so you won't know me any more. LOL
Time will tell of course. I am quite happy purchasing Helicos at these discounted prices. It could go from .15 to 3.00 again in the blink of an eye.
If they actually win one or all of the lawsuits, do you still think this company is worth .15/share?
Management is quiet but many of us have connected the dots as to what they're doing.
"They are waiting for us to run out of gas. They see the situation we're in and they think we'll eventually go away. But that's not going to happen."
Ivan Trifunovich, CEO/President of Helicos Biosciences
Friday, June 24 2011
http://www.bizjournals.com/boston/print-edition/2011/06/24/helicos-seeks-to-revive.html
Here's the deal (in my humble opinion anyway). Pacb isn't yet profitable, it has never made money. It gets most of it's fundng through gov't grants that everyone expect to dry up. It's machines are expensive, only to be outdone by their sheer size. Their "consumables" (stuff required to use the machine) are very costly. Their error rates are still behind their competitors (albeit getting better). Plus, and this is the biggy, everything is dropping like a rock right now, you simply cannot expect a non profitable company (that is going to continue to be unprofitable for the short term) to avoid the bloodshed. Even Illumina is dropping and they are profitable.
Having said all that, Pacb is a company worth keeping an eye on, but it is pure speculative right now and this is what happens with speculative stocks. I for one am very excited about it's prospects, it has the potential to be a game changer, but I have yet to buy a single stock share of this company and will continue to wait until they are closer to profitability or we have a better idea of just how bad they will be affected by the gov't budget cuts/grants.
Sure will suck when they lose their lawsuit.
ILMN, LIFE, and GNOM are all down big. PACB just part of the trend.
oh and Mr. Turner has cashed-out, did he know soemthing we didn't?
Automatic Sale at $12.07 per share.
(Proceeds of $362,100)
5-Jul-11 *37,400 PACB Automatic Sale at $12.03 per share.
(Proceeds of $449,922)
1-Jul-11 *500 PACB Automatic Sale at $12 per share.
(Proceeds of $6,000)
issues selling commercial product w/o certified quality system within US and rest of world. (FDA/MDD)
attrition is high, morale is low
poor management
manufacturing issues with poor yield on chips. contributing to relaibaility issues
Perhaps the word is getting out that the RS is not as great as it looks?
I believe PacBio will be offered for sale before they even get FDA certified, which they are not currently.
That doesn't answer the question.